	US 7,538,224 B2
	Hsp90 family protein inhibitors
Shinji Nara, Sunto-gun (Japan); Hiroshi Nakagawa, Sunto-gun (Japan); Yutaka Kanda, Tokyo (Japan); Takayuki Nakashima, Sunto-gun (Japan); Shiro Soga, Rockville, Md. (US); Jiro Kajita, Sunto-gun (Japan); Jun-ichi Saito, Sunto-gun (Japan); Yukimasa Shiotsu, Sunto-gun (Japan); and Shiro Akinaga, Sunto-gun (Japan)
Assigned to Kyowa Hakko Kogyo Co., Ltd., Tokyo (Japan)
Appl. No. 10/561,415 PCT Filed Jun. 10, 2004, PCT No. PCT/JP2004/008494 § 371(c)(1), (2), (4) Date Dec. 19, 2005, PCT Pub. No. WO2005/000778, PCT Pub. Date Jan. 06, 2005.
Claims priority of application No. 2003/185475 (JP), filed on Jun. 27, 2003.
Prior Publication US 2007/0032532 A1, Feb. 08, 2007
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 211/22 (2006.01); C07C 49/303 (2006.01)

U.S. Cl. 546—234 [568/332]

12 Claims

1. A benzoyl compound represented by general formula (IA):

{wherein

nA represents an integer of 1 to 5;

R^1Arepresents substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkoxycarbonyl, substituted or unsubstituted heterocyclic alkyl, substituted or unsubstituted aryl, CONR⁷R⁸(wherein R⁷and R⁸independently represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkanoyl, substituted or unsubstituted aryl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aralkyl, substituted or unsubstituted heterocyclic alkyl, or substituted or unsubstituted aroyl, or R⁷and R⁸form a substituted or unsubstituted heterocyclic group together with the adjacent nitrogen atom) or NR⁹R¹⁰(wherein R⁹and R¹⁰have the same meanings as the above R⁷and R⁸, respectively);

R^2Arepresents substituted or unsubstituted aryl;

R^3A, R^4Aand R^5Aeach represent a hydrogen atom; and

R^6Arepresents halogen or lower alkyl, and

wherein (i) substituents in the substituted lower alkyl, the substituted lower alkoxy and the substituted lower alkoxycarbonyl are 1 to 3 substituents which are the same or different selected from the group (A) consisting of hydroxy, oxo, cyano, nitro, carboxy, amino, halogen, substituted or unsubstituted lower alkoxy, cycloalkyl, lower alkanoyl, lower alkoxycarbonyl, lower alkylamino and di-lower alkylamino, wherein substituents in said substituted lower alkoxy are 1 to 3 substituents which are the same or different selected from the group consisting of hydroxy and halogen, and

(ii) substituents in the substituted cycloalkyl, the substituted heterocyclic alkyl, the substitued aryl, the substituted lower alkanoyl, the substituted heterocyclic group, the substituted aralkyl, the substituted aroyl and the substituted heterocyclic group formed together with the adjacent nitrogen atom are 1 to 3 substituents which are the same or different selected from the group (B) consisting of hydroxy, halogen, nitro, cyano, amino, carboxy, carbamoyl, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy, aralkyloxy, lower alkylsulfonyl, lower alkylsulfanyl, cycloalkyl, lower alkoxycarbonyl, lower alkylamino, di-lower alkylamino, lower alkanoyl, a heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic alkyloxy and substituted or unsubstituted heterocyclic carbonylalkyloxy, wherein substituents in said substituted lower alkyl, said substituted lower alkoxy and said substituted aryl are 1 to 3 substituents which are the same or different selected from the group consisting of hydroxy, halogen, lower alkoxy, cyano, lower alkylamino and di-lower alkylamino, and substituents in said substituted heterocyclic alkyloxy and said substituted heterocyclic carbonylalkyloxy are 1 to 3 substituents which are the same or different selected from the group consisting of hydroxy, halogen, lower alkyl, lower alkoxy and a heterocyclic group},

or a pharmaceutically acceptable salt thereof.